Cited by 157Protein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer

Open access

Molina-Arcas, Miriam, Hancock, David C., Sheridan, Clare, Kumar, Madhu S., Downward, Julian·2013·Cancer Discovery

DOI 10.1158/2159-8290.cd-12-0446PMC PMC3650991

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Using a panel of non–small cell lung cancer (NSCLC) lines, we show here that MAP-ERK kinase (MEK) and RAF inhibitors are selectively toxic for the KRAS-mutant genotype, whereas phosphoinositide 3-kinase (PI3K), AKT, and mTOR inhibitors are not. IGF1 receptor (IGF1R) tyrosine kinase inhibitors also show selectivity for KRAS-mutant lung cancer lines. Combinations of IGF1R and MEK inhibitors resulted in strengthened inhibition of KRAS-mutant lines and also showed improved effectiveness in autochthonous mouse models of Kras-induced NSCLC. PI3K pathway activity is dependent on basal IGF1R activity in KRAS-mutant, but not wild-type, lung cancer cell lines. KRAS is needed for both MEK and PI3K pathway activity in KRAS-mutant, but not wild-type, lung cancer cells, whereas acute activation of KRAS causes stimulation of PI3K dependent upon IGF1R kinase activity. Coordinate direct input of both KRAS and IGF1R is thus required to activate PI3K in KRAS-mutant lung cancer cells. Significance: It has not yet been possible to target RAS proteins directly, so combined targeting of effector pathways acting downstream of RAS, including RAF/MEK and PI3K/AKT, has been the most favored approach to the treatment of RAS-mutant cancers. This work sheds light on the ability of RAS to activate PI3K through direct interaction, indicating that input is also required from a receptor tyrosine kinase, IGF1R in the case of KRAS-mutant lung cancer. This suggests potential novel combination therapeutic strategies for NSCLC. Cancer Discov; 3(5); 548–63. ©2013 AACR. See related commentary by Chen and Sweet-Cordero, p. 491 This article is highlighted in the In This Issue feature, p. 471

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-12-0446

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Self-citation
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D. A. D., Joshi, M.-B., Harpole, D. H., Lancaster, J. M., Berchuck, A., et al. (2005) · Nature · doi:10.1038/nature04296 · Cited by 2,008
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Self-citation
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927

Flagged first, then by citations

Show all 52 references

1 of the 52 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–157 of 157

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
Weisberg, E., Nonami, A., Chen, Z., Nelson, E. A., Chen, Y., Liu, F., Cho, H., Zhang, J., Sattler, M., Mitsiades, C. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0902 · Cited by 20
Not just g RAS ping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
Ebi, H., Faber, A. C., Engelman, J. A., & Yano, S. (2014) · Cancer Science · doi:10.1111/cas.12383 · Cited by 18
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 17
Importance of the type I insulin-like growth factor receptor inHER2, FGFR2andMET-unamplified gastric cancer with and without Ras pathway activation
Saisana, M., Griffin, S. M., & May, F. E. B. (2016) · Oncotarget · doi:10.18632/oncotarget.10642 · Cited by 17
Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine
Lin, S.-L., Lin, C., Lee, W., Teng, C., Shyu, W., & Jeng, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911781 · Cited by 17
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 18
Combining targeted therapeutics in the era of precision medicine
Papadatos-Pastos, D., Miguel, M. J. D., & Yap, T. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.558 · Cited by 16
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma
Jamnongsong, S., Kueanjinda, P., Buraphat, P., Sakornsakolpat, P., Vaeteewoottacharn, K., Okada, S., Jirawatnotai, S., & Sampattavanich, S. (2022) · iScience · doi:10.1016/j.isci.2022.105182 · Cited by 14
Low-intensity light-induced drug release from a dual delivery system comprising of a drug loaded liposome and a photosensitive conjugate
Meerovich, I. G., Nichols, M. G., & Dash, A. K. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1710838 · Cited by 13
The complex journey of targeting RAS in oncology
Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14
Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer
El-Chaar, N. N., Piccolo, S., Boucher, K. M., Cohen, A. L., Chang, J. T., Moos, P. J., & Bild, A. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.005 · Cited by 12
Two Is Better Than One: Combining IGF1R and MEK Blockade as a Promising Novel Treatment Strategy Against KRAS-Mutant Lung Cancer
Ron, C., & Sweet-Cordero, A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0128 · Cited by 12
A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers
Rao, S., Du, G., Hafner, M. A., Subramanian, K., Sorger, P. K., & Gray, N. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006805 · Cited by 12
Addressing cancer invasion and cell motility with quantitative light microscopy
Zicha, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-05307-7 · Cited by 10
Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells
Shen, J., Li, L., Yang, T., Cheng, N., & Sun, G. (2019) · Molecules · doi:10.3390/molecules24030623 · Cited by 10
Quantitative Proteomic Analysis in Alveolar Type II Cells Reveals the Different Capacities of RAS and TGF-β to Induce Epithelial–Mesenchymal Transition
Zhou, Y., Hill, C. N., Yao, L., Li, J., Hancock, D. C., Downward, J., Jones, M. G., Davies, D. E., Ewing, R. M., Skipp, P. J. S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.595712 · Cited by 10
Self-citation
ADAMTS9-AS1 Long Non‑coding RNA Sponges miR‑128 and miR-150 to Regulate Ras/MAPK Signaling Pathway in Glioma
Javanmard, A.-R., Jahanbakhshi, A., Nemati, H., Mowla, S. J., & Soltani, B. M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01311-7 · Cited by 9
Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer
Jones, R. A., Franks, S. E., & Moorehead, R. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206948 · Cited by 8
NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
de Miranda, L. B. L., Lima, K., Coelho‐Silva, J. L., Traina, F., Kobayashi, S. S., & Machado‐Neto, J. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-21419-6 · Cited by 8
Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas
Li, J., Sordella, R., & Powers, S. (2016) · Scientific Reports · doi:10.1038/srep27891 · Cited by 8
Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment
Shen, Y., Crassini, K. R., Sandhu, S., Fatima, N., Christopherson, R. I., Mulligan, S. P., & Best, G. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1542148 · Cited by 8
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
LKB1 depletion-mediated epithelial–mesenchymal transition induces fibroblast activation in lung fibrosis
Xu, Z., Davies, E. R., Yao, L., Zhou, Y., Li, J., Alzetani, A., Marshall, B. G., Hancock, D. C., Wallis, T., Downward, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.034 · Cited by 7
Self-citation
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Hoo, W. P. Y., Siak, P. Y., & In, L. L. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190904163524 · Cited by 7
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
Hamilton, G., & Plangger, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1965123 · Cited by 7
Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
Nakhchi, B. G., Kosuru, R., & Chrzanowska‐Wodnicka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189853 · Cited by 7
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Stauffer, S., Roth, J. S., Hernandez, E. R., Kowalczyk, J. T., Sealover, N. E., Hebron, K. E., James, A. E., Isanogle, K. A., Riffle, L. A., Ileva, L. V., et al. (2024) · Cancers · doi:10.3390/cancers16132320 · Cited by 6
The end of KRAS, and other, cancers? A new way forward
Mallucci, L., & Wells, V. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.018 · Cited by 6
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W. B., Tabernero, J. M., Schmoll, H., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30453 · Cited by 6
Killing Tumors by Keeping Ras and PI3′ Kinase Apart
Yuan, T. L., & McCormick, F. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.015 · Cited by 5
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Entrialgo‐Cadierno, R., Morali, K., Feliu, I., Wang, Y., Evans, J., Yáñez-Bartolomé, M., López, I., Macaya, I., Cueto‐Ureña, C., Sin-Coscujuela, D., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.020 · Cited by 4
Oncogenic Ras deregulates cell-substrate interactions during mitotic rounding and respreading to alter cell division orientation
Ganguli, S., Wyatt, T., Nyga, A., Lawson, R. H., Meyer, T., Baum, B., & Matthews, H. K. (2023) · Current Biology · doi:10.1016/j.cub.2023.05.061 · Cited by 4
GRK6 Depletion Induces HIF Activity in Lung Adenocarcinoma
Yao, S., Ertay, A., Zhou, Y., Yao, L., Hill, C. N., Chen, J., Guan, Y., Sun, H., Ewing, R. M., Liu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654812 · Cited by 4
Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening
Williams, J. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_10 · Cited by 3
New Targets for Therapy in Lung Cancer
Mansfield, A. S., Dy, G. K., Ahn, M.-J., & Adjei, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00048-2 · Cited by 2
Cost and time-efficient construction of a 3′-end mRNA library from unpurified bulk RNA in a single tube
Choi, J., Hyun, J., Hyun, J., Kim, J.-H., Lee, J. H., & Bang, D. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01164-8 · Cited by 5
The effects of PIK3CA mutations on cervical cancer
Zhang, Y. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202455305025 · Cited by 3
ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity
Hebron, K. E., Perkins, O. L., Kim, A., Jian, X., Girald-Berlingeri, S. A., Lei, H., Shern, J. F., Conner, E. A., Randazzo, P. A., & Yohe, M. E. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0490 · Cited by 5
Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Feng, X., Ding, W., Ma, J., Liu, B., & Yuan, H. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210615161501 · Cited by 3
Predicting human clinical trial responses in mice
Gao, H., & Williams, J. A. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1162895 · Cited by 3
Identifying Drug Sensitivity Subnetworks with NETPHLIXPreprint
Kim, Y.-A., Basso, R. S., Wójtowicz, D., Hochbaum, D. S., Vandin, F., & Prztycka, T. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/543876 · Cited by 3
KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
Uras, I. Z., Trkulja, M. V., Salama, A. K. A. A., Horvath, J., Asnani, K., Trenk, C., Kubicek, S., Bilban, M., Moll, H. P., & Casanova, E. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01242-8 · Cited by 1
KRAS combination strategies: How well aligned is clinical and preclinical research?
Nadal, E., Ambrogio, C., Santamarı́a, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 2
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Yang, P., & Li, Y. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01514-x · Cited by 1
Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model
Kobayashi, K., Terai, H., Yasuda, H., Hamamoto, J., Hayashi, Y., Takeuchi, O., Mitsuishi, Y., Masuzawa, K., Manabe, T., Ikemura, S., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.110 · Cited by 1
ecancermedicalscience
Mazzarella, L. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.390 · Cited by 1
Oncogenic RAS Signalling Promotes Tumour Immunoresistance by Stabilising PD-L1 mRNA
Coelho, M. (2017) · UCL Discovery (University College London) · Cited by 1
Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
Britt, R. R. (2014)
Characterization of select downstream effectors of oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia
Gusscott, S. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0228205
Comprehensive Library of Drug Response and Pan-Omic Analysis Identified Therapeutic Candidates and Accompanying Prognostic Biomarkers for Asian CholangiocarcinomaPreprint
Jamnongsong, S., Kueanjinda, P., Buraphat, P., Sakornsakolpat, P., Vaeteewoottacharn, K., Okada, S., Jirawatnotai, S., & Sampattavanich, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4131651
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy, F. M., Turner, A. L., Marensi, V., & MacEwan, D. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1441938
Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinomaPreprint
Trécesson, S. D. C., East, P., Pillsbury, C. E., dos Santos, M. S., Cha, H., Colliver, E., Gilmore, T., Rana, S., Moore, C., Lighterness, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690426
Self-citation
Additional file 1 of Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice
Xiong, H.-J., Yu, H.-Q., Zhang, J., Fang, L., Wu, D., Lin, X.-T., & Xie, C.-M. (2023) · Figshare · doi:10.6084/m9.figshare.24883563
STRUCTURE-BASED OPTIMIZATION OF ADAGRASIB (MRTX849) ANALOGUES: ADVANCED COMPUTATIONAL FRAMEWORK FOR KRAS G12D INHIBITOR DESIGN
Varol, A. (2025) · Mugla Journal of Science and Technology · doi:10.22531/muglajsci.1826880
Network pharmacology-based exploration of therapeutic targets and key pathways of gastrodin in lung cancer
Zhou, Y., & Cheng, F. (2025) · Integrate Medicine · doi:10.61958/imcl2577
A Bidirectional IL-34–IGF-1 Inflammatory Axis Fuels KRAS-Mutant Cancer ProgressionPreprint
Žák, J., Chen, H., Wang, E., Ozark, P., Mognol, G. P., PARK, M. D.-Y., Fournier, N., Chaudary, P., Hu, J., Shepard, R. M., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.07.14.738492

Authors: Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J.
Affiliations: Authors' Affiliations: 1Signal Transduction Laboratory, Cancer Research UK London Research Institute; and 2Lung Cancer Group, Division of Cancer Biology, The Institute of Cancer Research, London, United Kingdom
Institute of Cancer Research (GB)
Corresponding author: Downward, Julian
ORCID: Hancock, David C.
Downward, Julian
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2013-05-01
Volume: 3
Issue: 5
Pages: 548-563
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-12-0446
PMC: PMC3650991
OpenAlex: W2169546036
Cited by: 157
References: 52
Citations by year: 2026: 3 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 19 · 2020: 12 · 2019: 11 · 2018: 11 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 21 · 2013: 10
FWCI: 8.67
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Cancer Research UK (A3570, 15680)
European Commission
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: KRAS mutation, non-small cell lung cancer, IGF-1 receptor, PI3K activation, MEK inhibitors, RAF inhibitors, PI3K/AKT/mTOR inhibitors, combination therapy, Ras signaling, receptor tyrosine kinase, drug selectivity
MeSH terms: Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mice, Transgenic, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Receptor, IGF Type 1, ras Proteins, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks